Public Release: 

The first M&A in aging bioinformatics

Insilico Medicine and InSilicoScreen merge to take human aging research to the next level

InSilico Medicine, Inc.

"The most valuable assets in bioinformatics companies are its people and at Insilico Medicine we constantly hire top talent through hackathons, challenges and competitions. Quentin Vanhaelen is an army of one who has developed a vertically-integrated system which synthesises data, performs complex simulations using manually-curated and automatically-annotated databases of molecular interactions primarily in Fortran, and produces impressive LaTeX reports. We are happy to have him join our team", said Alex Zhavoronkov, PhD, CEO of Insilico Medicine, Inc.

Since 2013, under Dr. Vanhaelen's leadership, scientists at InSilicoScreen have assembled large databases of kinetic protein interactions and built sophisticated signal transmission, regulation of cell metabolism, autophagy, cell cycle and other models. The sole aim was to build models of human aging and regenerative processes to find new interventions and test the current ones on multiple levels from single cells to the entire organs. The company developed a service-oriented business model and engaged with multiple academic and commercial groups worldwide.

"I have known Insilico Medicine for over one and a half years and they were always under the spotlights of innovations, but I realized that they are very focused and with my models they can use their real human data and biologically-relevant pathway activation algorithms with my time-series simulations for many applications, including deep learning. I really like working with the team and will spend my time between Baltimore, Brussels and Moscow", said Quentin Vanhaelen, PhD, founder and ex-CEO of InSilicoScreen.

Aging research is a very altruistic endeavor, but building a sustainable business model is often challenging. As part of its business model, Insilico Medicine provides contract research, data quality analysis, cross-platform harmonization, pathway activation analysis, biomarker development, clinical trials pipeline review and scoring, portfolio review, and drug scoring and drug repurposing services to large pharmaceutical and cosmetics companies, hedge funds, academic institutions, and other organizations with large biological or pharmaceutical databases.

"We are very happy that our flagship portfolio company has expanded its scientific leadership with another eccentric, but amazingly brilliant theoretical physicist-turned systems biologist, who managed to build surprisingly sophisticated models of human biological networks that are fit for dynamic simulations" , said Dmitry Kaminskiy, senior partner of Deep Knowledge Ventures.

###

About Insilico Medicine, Inc

Insilico Medicine, Inc. is a bioinformatics company located at the Emerging Technology Centers at the Johns Hopkins University Eastern campus in Baltimore. It utilizes advances in genomics, big data analysis and deep learning for in silico drug discovery and drug repurposing for aging and age-related diseases. The company pursues internal drug discovery programs in cancer, Parkinson's, Alzheimer's, sarcopenia and geroprotector discovery and provides services to pharmaceutical companies. Brief company video:

https://www.youtube.com/watch?v=l62jlwgL3v8

About InSilicoScreen

InSilicoScreen is a Belgian aging bioinformatics company based in Brussels. It provides clients in the pharmaceutical industry and academia with a reliable and specific information about the global dynamic of the cellular networks by combining the efficient numerical and mathematical methods together with an in-depth understanding of the underlying molecular processes.

http://www.InSilicoScreen.eu

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.